doi: 10.1194/jlr.R800053-JLR200
MAFLD, which was renamed MASLD by an international panel of experts in 2023, refers to the same category of steatotic liver disease driven by metabolic dysfunction as the latter term with only the nomenclature adjusted to more accurately reflect the core pathological feature of hepatic steatosis
rare adverse events not yet detectable from smaller trial populations Limitation : Phase 2 safety data insufficient for comprehensive risk-benefit assessment Dosing and Administration Comparison# Semaglutide Dosing# Survodutide Dosing# Use Case Recommendations# Choose Semaglutide When:# Proven efficacy with FDA-approved dosing is required for current clinical use Cardiovascular risk reduction is a treatment goal (SELECT trial evidence) Oral dosing is preferred (Rybelsus option) Comprehensive safety data and well-characterized risk profile are priorities Type 2 diabetes is the primary indication alongside weight management Choose Survodutide When:# MASH/NASH is a primary treatment target, where glucagon-mediated hepatic fat oxidation provides a differentiated mechanism Maximum weight loss beyond GLP-1 monotherapy is the goal, pending Phase 3 confirmation Energy expenditure enhancement is desired alongside appetite suppression Clinical trial participation is an option for accessing the compound before potential approval Can They Be Combined?# Combining semaglutide with survodutide is not pharmacologically rational, as survodutide already contains GLP-1R agonist activity
The process is the same as any other peptide, but MOTS-C has a unique consideration: the doses are relatively large (5-10mg) compared to peptides like BPC-157 or semaglutide, which means the dilution choice matters more for injection volume
Dose adjustments during maintenance depend on individual response
In contrast to other polyposis syndromes, the polyps in Cronkhite-Canada syndrome patients can develop throughout the gastrointestinal tract (except the esophagus)[107]
